Psychedelic Trials Explore New Approaches to End-of-Life Care
A new film and ongoing clinical trials are examining the potential of psychedelic medicine, particularly psilocybin, to improve the experience of dying and, consequently, how we approach life.
The film, Edge of Life, highlights an Australian-first clinical trial conducted at St Vincent’s Hospital in Melbourne led by Dr. Justin Dwyer and Dr. Margaret Ross. The trial investigates the use of psilocybin in palliative care, building on growing research into the therapeutic benefits of psychedelics. Dr. Dwyer noted that his work is “the most life-affirming environment I’ve ever worked in, because it’s all about living,” despite dealing with end-of-life patients. He also pointed out a significant gap in medical training, stating, “I learned nothing about how to die” during his 20 years of schooling.
The research extends beyond Western medicine, incorporating perspectives from Amazonian and Maya shamans who have long utilized psychedelics in spiritual and healing practices. Dr. Dwyer and Dr. Ross themselves participated in an ayahuasca ceremony guided by Muka Yawanawa, a shaman of the Yawanawá people, to deepen their understanding. This exploration of ancient wisdom alongside modern science reflects a growing interest in holistic approaches to death and dying, a topic often avoided in mainstream discourse. Further research into palliative care can be found at the World Health Organization.
The film features the experiences of trial participants, identified only as Flavia and Ros, and also includes insights from Dr. Chris Kerr, who runs a palliative care program in New York. Officials involved in the trial emphasize the importance of integrating scientific rigor with traditional knowledge to address a universal human experience. This research comes as more countries consider the potential benefits of psychedelic-assisted therapy for a range of mental health conditions, as recently discussed by the DEA.
Researchers plan to continue analyzing data from the clinical trial and exploring opportunities to expand the research to other populations and settings.
